TWI853027B - N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 - Google Patents

N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 Download PDF

Info

Publication number
TWI853027B
TWI853027B TW109116067A TW109116067A TWI853027B TW I853027 B TWI853027 B TW I853027B TW 109116067 A TW109116067 A TW 109116067A TW 109116067 A TW109116067 A TW 109116067A TW I853027 B TWI853027 B TW I853027B
Authority
TW
Taiwan
Prior art keywords
crystalline form
hydrochloride
ascimenide
chlorodifluoromethoxy
hydroxypyrrolidin
Prior art date
Application number
TW109116067A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110823A (zh
Inventor
史蒂芬妮 凱 達德
阿諾德 葛連德瑞
維吉尼亞 羅薩基
艾曼紐 瑟福爾特
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202110823A publication Critical patent/TW202110823A/zh
Application granted granted Critical
Publication of TWI853027B publication Critical patent/TWI853027B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109116067A 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 TWI853027B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962848857P 2019-05-16 2019-05-16
US62/848,857 2019-05-16
US201962949599P 2019-12-18 2019-12-18
US62/949,599 2019-12-18

Publications (2)

Publication Number Publication Date
TW202110823A TW202110823A (zh) 2021-03-16
TWI853027B true TWI853027B (zh) 2024-08-21

Family

ID=70775449

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109116067A TWI853027B (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
TW113128176A TW202444706A (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113128176A TW202444706A (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Country Status (13)

Country Link
US (3) US11407735B2 (https=)
EP (1) EP3969117B1 (https=)
JP (2) JP2022532404A (https=)
KR (1) KR102945602B1 (https=)
CN (1) CN114144232A (https=)
AU (1) AU2020276701B2 (https=)
BR (1) BR112021022712A2 (https=)
CA (1) CA3139812A1 (https=)
CL (1) CL2021003011A1 (https=)
IL (1) IL287995A (https=)
MX (1) MX2021013970A (https=)
TW (2) TWI853027B (https=)
WO (1) WO2020230099A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
ES3057399T3 (en) 2020-01-28 2026-03-02 Tapi Czech Ind S R O Solid state forms of asciminib and processes for the preparation thereof
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN114369085B (zh) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 盐酸Asciminib的制备方法
WO2024100212A1 (en) 2022-11-10 2024-05-16 Synthon B.V. Crystalline form of asciminib hydrochloride
WO2024257116A1 (en) * 2023-06-13 2024-12-19 Natco Pharma Limited Novel polymorphic forms of asciminib and its pharmaceutical salts thereof
WO2025032514A1 (en) * 2023-08-07 2025-02-13 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171639A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
HUE031227T2 (en) 2012-12-27 2017-07-28 Zentiva Saglik Ueruenleri San Ve Tic A S Dry granulation process for preparing metformin tablet compositions and compositions thereof
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3292870A1 (en) 2016-09-08 2018-03-14 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Fibronectin for use in the treatment of leukemia
EP3519400A1 (en) 2016-09-27 2019-08-07 Novartis AG Surfactant systems for crystallization of organic compounds
EP3700516B1 (en) 2017-10-27 2024-01-24 Sonic Master Limited Inhibitors of dux4 induction for regulation of muscle function
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171639A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Also Published As

Publication number Publication date
US12252478B2 (en) 2025-03-18
CA3139812A1 (en) 2020-11-19
IL287995A (en) 2022-01-01
EP3969117A1 (en) 2022-03-23
CL2021003011A1 (es) 2022-09-09
WO2020230099A1 (en) 2020-11-19
KR102945602B1 (ko) 2026-03-31
JP2022532404A (ja) 2022-07-14
KR20220009414A (ko) 2022-01-24
US20230089503A1 (en) 2023-03-23
US20230074064A1 (en) 2023-03-09
BR112021022712A2 (pt) 2022-03-29
US11407735B2 (en) 2022-08-09
MX2021013970A (es) 2022-01-04
US12252479B2 (en) 2025-03-18
AU2020276701A8 (en) 2022-05-12
EP3969117B1 (en) 2026-03-25
AU2020276701A1 (en) 2022-01-06
US20200361904A1 (en) 2020-11-19
TW202110823A (zh) 2021-03-16
JP2024095697A (ja) 2024-07-10
AU2020276701B2 (en) 2023-11-23
TW202444706A (zh) 2024-11-16
CN114144232A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
TWI853027B (zh) N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
EP3969449B1 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
TWI619495B (zh) Ｃ-ｍｅｔ調節劑醫藥組合物
JP7659097B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
EP2582689A1 (en) New polymorphic form of imatinib base and preparation of salts thereof
WO2016092561A2 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
JP2018515566A (ja) 医薬組成物
EP1880992A1 (en) Stable modifications of tegaserod hydrogen maleate
JP4498679B2 (ja) 結晶性イソキサゾール誘導体およびその医薬製剤
US20240293420A1 (en) Pharmaceutical composition, preparation, and preparation method therefor and use thereof
RU2836337C2 (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
KR20260055492A (ko) N-[4-(클로로디플루오로메톡시)페닐]-6-[(3r)-3-히드록시피롤리딘-1-일]-5-(1h-피라졸-5-일)피리딘-3-카복사미드의결정질 형태
JP4684545B2 (ja) 溶出性の良好なイソキサゾール誘導体経口製剤
HK40127061A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40026069A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
HK1196017A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations
HK1196017B (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations